4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads.

Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. 

Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.


Biotechnology

Health Care

Life Sciences

Therapeutics

4basebio

Heikki Lanckriet

Zoe Whiffen

Amy Walker

David Roth

The Scientific Team at 4basebio is responsible for the research, development, and optimization of the company's synthetic DNA and non-viral vector technologies. Their work includes designing and synthesizing application-specific nucleic acids, developing targeted delivery systems like Hermes™ nanoparticles, and ensuring the safety, customization, and efficacy of these solutions for use in cell and gene therapies, vaccines, and therapeutics. This team collaborates closely across various disciplines to drive innovation and address the limitations of current genetic technologies.

Scientific Team

Quality Control

Scientific Team

About

Team members

Other teams at 4basebio

Quality Control